Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like Boston???s NeoSync Nabs $13 Million in Financing August 10, 2017 Little Known Life Science Hedge Fund Dethroning Ackman's Pershing Square January 18, 2018 Rebiotix Continues Management Team Expansion With Appointment Of As Chief Business Officer June 19, 2017
Rebiotix Continues Management Team Expansion With Appointment Of As Chief Business Officer June 19, 2017
